[Skip to Navigation]
Sign In
Comment & Response
May 2018

Assessing Metronomic Chemotherapy for Progressive Pediatric Solid Malignant Tumors—Reply

Author Affiliations
  • 1Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India
  • 2Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India
JAMA Oncol. 2018;4(5):744. doi:10.1001/jamaoncol.2017.4891

In Reply We thank Fang et al for their interest in our study.1 Just eyeballing the progression-free and overall survival Kaplan-Meier curves, it is evident that survival experiences in both arms of the study are essentially similar without any meaningful difference. The restricted mean survival (event-free) time (RMST) up to a specific time point is an attractive new but seldom-used alternative approach to evaluate differences in the Kaplan-Meier curves, if the curves show apparent differences and the proportional hazards assumption is not plausible. When Kaplan-Meier curves overlap with no apparent differences, the proportional hazards assumption is redundant. Furthermore, the RMST approach needs a prespecification of time point because it varies with the time point at which we truncate our graphs for assessing clinically meaningful outcomes.

Add or change institution
×